MedTrace Logo

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

NCT03422445 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-02-05

No results posted yet for this study

Summary

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

Conditions

Interventions

DRUG

Apatinib

Apatinib：500mg/d，qd，po，d1-28

DRUG

Temozolomide

Temozolomide：300mg/d，qd，po，d1-5

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Jun Guo, MD，PHD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-08
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422445 on ClinicalTrials.gov